Q32 BIO INC. | MedPath

Q32 Bio Restructures to Advance Bempikibart Development for Alopecia Areata Treatment

3 months ago

• Q32 Bio announces strategic restructuring to focus on bempikibart development for alopecia areata, discontinuing its ADX-097 renal trials to extend cash runway through 2026. • Promising SIGNAL-AA Part A trial data shows sustained SALT score improvements and potential remittive effects for bempikibart, with continued patient response up to 55 weeks post-treatment. • Company plans to initiate an open-label extension study and SIGNAL-AA Part B trial in first half of 2025, with topline data expected in first half of 2026.

FDA Accepts NDA for Oral Semaglutide 25 mg for Weight Management and Cardiovascular Risk Reduction

5 years ago

• The FDA has accepted the New Drug Application for oral semaglutide 25 mg, positioning it as a potential daily treatment option for both weight management and cardiovascular risk reduction. • If approved, oral semaglutide 25 mg would represent a significant advancement in GLP-1 receptor agonist therapy, offering patients a non-injectable alternative for obesity treatment. • The acceptance comes amid growing clinical interest in GLP-1 therapies, with this higher dose formulation potentially addressing the increasing demand for effective weight management solutions.